ECE2024 Poster Presentations Diabetes, Obesity, Metabolism and Nutrition (130 abstracts)
Testosterone levels in men with type 2 diabetes: impact of statins and dyslipidemia
Anis Grassa 1 , Manel Jemel 1 , Salma Salhi 1 , Brahim Khalfa 1 , Asma Krir 2 , Ahlem Benhmid 2 , Marwa Chiboub 1 , Radhouane Gharbi 1 & Ines Kammoun 1
1National Institute of Nutrition and Food Technologies, Zouheir Kallel; 2Pasteur Institute of Tunis
Introduction: Hypogonadism (HG), a condition characterized by insufficient testosterone levels, is a prevalent concern in men with Type 2 Diabetes (T2D). Simultaneously, the use of statins and the presence of dyslipidemia are common aspects of the medical management of individuals with T2D. This study investigates the intricate relationship between HG, statin therapy, and dyslipidemia in men with T2D, aiming to unravel potential correlations and shed light on the complex health dynamics within this population.MethodsThis is a cross-sectional study that included 250 male patients aged 40 to 65 diagnosed with T2D, recruited from outpatient clinics. All patients underwent lipid and hormonal assessments. HG was considered in the presence of specific criteria: Total Testosterone (TT) levels below 231 ng/dL, Free Testosterone (FT) levels below 6.5 ng/dL, or Bioavailable Testosterone (BT) levels below 150 ng/dL.ResultsThe median age of our cohort was 58 years, with an interquartile range of [52.7-62], spanning from 40 to 65 years. Regarding blood lipids, the average levels of total cholesterol (TC), triglycerides (TG), and high-density lipoprotein cholesterol (HDLc) were 4.14±0.96 mmol/L, 1.44±0.89 mmol/L, and 1.03±0.22 mmol/L, respectively. Dyslipidemia was noted in 72.3% of patients, predominantly marked by hypoHDLemia (55.7%) followed by hypertriglyceridemia (27.7%). Additionally, 12.8% of patients exhibited hypercholesterolemia . Notably, 69.2% of participants were under statin therapy. Concerning TT levels, The average level was 438.8 172.1 ng/dL. No significant difference was observed between the statin group (434.0±158.2 ng/dL) and the non-statin group (453.6±201.2 ng/dL) (p=0.414). The analysis of HG prevalence between the statin (69.7%) and non-statin groups (71.1%) did not reveal a significant difference (p=0.829).ConclusionThese findings suggest that in the studied cohort of men with T2D, dyslipidemia and statin therapy did not significantly impact total testosterone levels or the prevalence of hypogonadism. Further research may be warranted to explore additional factors influencing hormonal health in this population.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more